Menu Close

KFA Private Wealth Group LLC Acquires 507 Shares of Johnson & Johnson (NYSE:JNJ)

view original post

KFA Private Wealth Group LLC boosted its holdings in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 8.8% in the 1st quarter, Holdings Channel.com reports. The institutional investor owned 6,246 shares of the company’s stock after buying an additional 507 shares during the period. Johnson & Johnson makes up approximately 0.6% of KFA Private Wealth Group LLC’s investment portfolio, making the stock its 29th biggest position. KFA Private Wealth Group LLC’s holdings in Johnson & Johnson were worth $1,107,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in the business. Family CFO Inc purchased a new stake in Johnson & Johnson during the fourth quarter valued at about $26,000. Steward Financial Group LLC purchased a new stake in Johnson & Johnson during the fourth quarter valued at about $34,000. Joseph P. Lucia & Associates LLC purchased a new stake in Johnson & Johnson during the first quarter valued at about $38,000. Advocacy Wealth Management Services LLC raised its position in Johnson & Johnson by 41.4% during the first quarter. Advocacy Wealth Management Services LLC now owns 229 shares of the company’s stock valued at $41,000 after purchasing an additional 67 shares in the last quarter. Finally, Gibson Wealth Advisors LLC purchased a new stake in Johnson & Johnson during the fourth quarter valued at about $49,000. Institutional investors own 68.78% of the company’s stock.

Johnson & Johnson Stock Up 0.2 %

Shares of NYSE:JNJ opened at $174.52 on Friday. Johnson & Johnson has a 1 year low of $155.72 and a 1 year high of $186.69. The company has a market cap of $459.23 billion, a PE ratio of 25.40, a P/E/G ratio of 3.28 and a beta of 0.63. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.39 and a quick ratio of 1.14. The stock’s 50-day moving average is $175.95 and its 200 day moving average is $174.39.

Johnson & Johnson (NYSE:JNJGet Rating) last announced its quarterly earnings results on Tuesday, July 19th. The company reported $2.59 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.57 by $0.02. The company had revenue of $24.02 billion for the quarter, compared to the consensus estimate of $23.85 billion. Johnson & Johnson had a return on equity of 36.56% and a net margin of 19.21%. Johnson & Johnson’s revenue was up 3.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.48 EPS. Sell-side analysts anticipate that Johnson & Johnson will post 10.05 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 6th. Shareholders of record on Tuesday, August 23rd will be given a dividend of $1.13 per share. The ex-dividend date of this dividend is Monday, August 22nd. This represents a $4.52 annualized dividend and a yield of 2.59%. Johnson & Johnson’s payout ratio is 65.79%.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 40,000 shares of Johnson & Johnson stock in a transaction that occurred on Friday, June 10th. The stock was sold at an average price of $173.00, for a total transaction of $6,920,000.00. Following the sale, the executive vice president now directly owns 71,311 shares of the company’s stock, valued at approximately $12,336,803. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, EVP Kathryn E. Wengel sold 40,000 shares of the business’s stock in a transaction that occurred on Friday, June 10th. The stock was sold at an average price of $173.00, for a total value of $6,920,000.00. Following the sale, the executive vice president now directly owns 71,311 shares of the company’s stock, valued at approximately $12,336,803. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CAO Robert J. Decker sold 8,462 shares of the business’s stock in a transaction that occurred on Thursday, May 26th. The stock was sold at an average price of $180.00, for a total value of $1,523,160.00. Following the completion of the sale, the chief accounting officer now directly owns 15,473 shares in the company, valued at $2,785,140. The disclosure for this sale can be found here. Insiders own 0.35% of the company’s stock.

Wall Street Analysts Forecast Growth

JNJ has been the topic of a number of research reports. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, May 17th. Morgan Stanley lifted their price objective on Johnson & Johnson from $173.00 to $174.00 and gave the stock an “equal weight” rating in a report on Friday, July 8th. Raymond James lifted their price objective on Johnson & Johnson from $195.00 to $196.00 and gave the stock an “outperform” rating in a report on Wednesday, April 20th. The Goldman Sachs Group lifted their price objective on Johnson & Johnson from $163.00 to $181.00 and gave the stock a “neutral” rating in a report on Tuesday, April 12th. Finally, Daiwa Capital Markets assumed coverage on Johnson & Johnson in a report on Wednesday, June 22nd. They issued an “outperform” rating on the stock. Four investment analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Johnson & Johnson presently has an average rating of “Moderate Buy” and a consensus price target of $189.89.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Featured Stories

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Receive News & Ratings for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.